Roth Capital rated Buy ARDEA BIOSCIENCES (NASDAQ: RDEA) on 02/19/2010, when the stock price was $15.13. Since then, ARDEA BIOSCIENCES has gained 111.24% as of 06/19/2012's recent price of $31.96.
If you would have followed this Roth Capital's recommendation on RDEA, you would have gained 111.23% of your investment in 851 days.

Ardea Biosciences, Inc. is a biotechnology company focused on the discovery and development of small-molecule therapeutics for the treatment of human immunodeficiency virus (HIV), cancer and inflammatory diseases, including gout. The Company's portfolio of product candidates include RDEA806 and 2nd generation non-nucleoside reverse transcriptase inhibitor (NNRTI) for HIV indication; RDEA594 for gout; RDEA119 for cancer; RDEA119 for inflammation, and mitogen-activated ERK kinase (MEK) inhibitor for cancer/inflammation.

ROTH researches emerging growth equities in the media, technology, telecommunications, healthcare, consumer, energy and industrial sectors. The research is focused on companies with market capitalization of between $100 million - $1 billion. Our coverage universe includes approximately 180 small cap growth companies around the globe including several companies from China. With an average market cap of approximately $500 million, our objective is to identify rapidly growing companies with significant long term growth prospects.

Marked as spam